Lung Cancer
Volume 70, Issue 2 , Pages 180-187 , November 2010

Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: A phase I dose-escalation study

  • Martin Reck

      Affiliations

    • Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf 22927, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 4102 601188; fax: +49 4102 691317.
    • ,
  • Norbert Frickhofen

      Affiliations

    • Department of Oncology, HSK, Dr Horst Schmidt Klinik, Wiesbaden, Germany
    • ,
  • Susana Cedres

      Affiliations

    • Oncology Department, Vall d’Hebron University Hospital, Barcelona, Spain
    • ,
  • Ulrich Gatzemeier

      Affiliations

    • Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf 22927, Germany
    • ,
  • David Heigener

      Affiliations

    • Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf 22927, Germany
    • ,
  • Heinz-Georg Fuhr

      Affiliations

    • Department of Oncology, HSK, Dr Horst Schmidt Klinik, Wiesbaden, Germany
    • ,
  • Aron Thall

      Affiliations

    • Pfizer Oncology, La Jolla, CA, USA
    • ,
  • Silvana Lanzalone

      Affiliations

    • Pfizer Italia Srl, Milan, Italy
    • ,
  • Patricia Stephenson

      Affiliations

    • Rho, Inc., Chapel Hill, NC, USA
    • ,
  • Ana Ruiz-Garcia

      Affiliations

    • Pfizer Oncology, La Jolla, CA, USA
    • ,
  • Richard Chao

      Affiliations

    • Pfizer Oncology, La Jolla, CA, USA
    • ,
  • Enriqueta Felip

      Affiliations

    • Oncology Department, Vall d’Hebron University Hospital, Barcelona, Spain

Received 29 September 2009 ,Revised 21 January 2010 ,Accepted 24 January 2010.

References 

  1. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92–98
  2. Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003;21(16):3016–3024
  3. D’Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, Shepherd FA. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol. 2005;23(13):2926–2936
  4. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: NSCLC v.2.2008. http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf.
  5. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–2550
  6. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsch V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009;27(8):1227–1234
  7. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trail. Lancet. 2009;373(9674):1525–1531
  8. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003;2(5):471–478
  9. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9(1):327–337
  10. Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W, et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis. 2003;20(8):757–766
  11. O’Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003;101(9):3597–3605
  12. Shikada Y, Yonemitsu Y, Koga T, Onimaru M, Nakano T, Okano S, et al. Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas. Cancer Res. 2005;65(16):7241–7248
  13. Yuan A, Yu CJ, Kuo SH, Chen WJ, Lin FY, Luh KT, et al. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol. 2001;19(2):432–441
  14. Hasumi Y, Klosowska-Wardega A, Furuhashi M, Ostman A, Heldin CH, Hellberg C. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling. Int J Cancer. 2007;121(12):2606–2614
  15. Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol. 2008;26(4):650–656
  16. Brahmer JR, Govindan R, Novello S, Rosell R, Belani CP, Atkins JN, et al. Efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC): results from a phase II study. J Clin Oncol. 2007;25(18S):[abstract 7542]
  17. Christensen JG, Hall C, Hollister BA . Antitumor efficacy of sunitinib malate in concurrent and sequential combinations with standard chemotherapeutic agents in non-small cell lung cancer (NSCLC) nonclinical models. [abstract 1433] In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research. San Diego, CA, USA, April 12–16, 2008. 2008;
  18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92(3):205–216
  19. McCort-Tipton MM, Brus T. Validation of a method for the determination of gemcitabine and its metabolite dFdU in human plasma by HPLC with MS/MS detection. Madison, WI, USA: Covance Laboratories, Inc.; 2005;[Covance Study No. 2100-765]
  20. Breeze M . Validation of a method for the determination of platinum from cisplatin in human plasma ultrafiltrate using ICP/MS. Madison, WI, USA: Covance Laboratories, Inc.; 2006;[Covance Study No. 2100-741]
  21. Johnson A. Validation report: the measurement of SU011248, SU012662 and SU012487 in EDTA human plasma. West Lafayette, IN, USA: BAS Analytics; 2002;[BAS Analytics Project No. 1000-0499]
  22. Koukourakis MI, Giatromanolaki A, O’Byrne KJ, Comley M, Whitehouse RM, Talbot DC, et al. Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer. Br J Cancer. 1997;75(4):477–481
  23. Crinò L, Scagliotti G, Marangolo M, Figoli F, Clerici M, De Marinis F, et al. Cisplatin–gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol. 1997;15(1):297–303
  24. Cardenal F, Lopez-Cabrerizo MP, Anton A, Alberola V, Massuti B, Carrato A, et al. Randomized phase III study of gemcitabine–cisplatin versus etoposide–cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 1999;17(1):12–18
  25. Gaafar RM, Hamza R, Khaled HM, Elserafi M, Mansour O, Karim NA, et al. Gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: National Cancer Institute Cairo experience. J Egypt Natl Canc Inst. 2004;16(1):1–7
  26. Kroep JR, Peters GJ, van Moorsel CJ, Catik A, Vermorken JB, Pinedo HM, et al. Gemcitabine–cisplatin: a schedule finding study. Ann Oncol. 1999;10(12):1503–1510
  27. Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2000;18(1):122–130
  28. Piguet D, Chapuis B. Recombinant human granulocyte-macrophage colony-stimulating factor in acquired or chemotherapy-induced neutropenia. An open clinical trial. Acta Oncol. 1994;33(6):639–643
  29. Mayordomo JI, Rivera F, Díaz-Puente MT, Lianes P, Colomer R, López-Brea M, et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst. 1995;87(11):803–808

PII: S0169-5002(10)00059-0

doi: 10.1016/j.lungcan.2010.01.016

Lung Cancer
Volume 70, Issue 2 , Pages 180-187 , November 2010

Article Tools

* Image Usage & Resolution